Literature DB >> 19336017

Targeting angiogenesis in bladder cancer.

Aymen A Elfiky1, Jonathan E Rosenberg.   

Abstract

In most cases, death from bladder cancer results from metastatic disease. Understanding the closely linked mechanisms of invasion, metastasis, and angiogenesis in bladder cancer has allowed development of new therapeutic strategies that may lead to improvements in patient survival. Vascular endothelial growth factor levels appear to be prognostic for outcomes in advanced bladder cancer, and preclinical evaluation of angiogenesis inhibition demonstrates anticancer activity. Antiangiogenic agents such as sunitinib, sorafenib, and bevacizumab are being tested in advanced bladder cancer. This review highlights the key developments in antiangiogenic therapy as it relates to bladder cancer treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19336017     DOI： 10.1007/s11912-009-0034-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  52 in total

1.  Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder.

Authors:  W D Beecken; T Engl; Judith Hofmann; D Jonas; R Blaheta
Journal:  J Cell Mol Med       Date:  2005 Jul-Sep       Impact factor: 5.310

2.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Authors:  C J Sweeney; K D Miller; S E Sissons; S Nozaki; D K Heilman; J Shen; G W Sledge
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

4.  Molecular mediators of angiogenesis in bladder cancer.

Authors:  S C Campbell; O V Volpert; M Ivanovich; N P Bouck
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

5.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Authors:  J P Crew; T O'Brien; M Bradburn; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

6.  Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer.

Authors:  Jonathan C Goddard; Christopher D Sutton; Peter N Furness; Kenneth J O'Byrne; Roger C Kockelbergh
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

7.  Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.

Authors:  B A Teicher; S A Holden; G Ara; N P Dupuis; F Liu; J Yuan; M Ikebe; Y Kakeji
Journal:  Int J Cancer       Date:  1995-05-29       Impact factor: 7.396

8.  Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.

Authors:  Darren W Davis; Keiji Inoue; Colin P N Dinney; Daniel J Hicklin; James L Abbruzzese; David J McConkey
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

9.  Interstitial hypertension in superficial metastatic melanomas in humans.

Authors:  Y Boucher; J M Kirkwood; D Opacic; M Desantis; R K Jain
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  7 in total

Review 1.  Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Authors:  Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 2.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 3.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

Review 4.  Novel strategies for treating relapsed/refractory urothelial carcinoma.

Authors:  Gopa Iyer; Matthew I Milowsky; Dean F Bajorin
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

5.  Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior.

Authors:  Yong Zhao; Mingjie An; He Zhang; Dengxu Tan; Xue Chen; Pengpeng Wu; Weijun Qin; Caiqin Zhang; Changhong Shi
Journal:  RSC Adv       Date:  2019-06-06       Impact factor: 4.036

6.  CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer.

Authors:  Yang Xiong; Fang Huang; Xiaozhou Li; Zhi Chen; Deyun Feng; Haiying Jiang; Wei Chen; Xiangyang Zhang
Journal:  Int J Oncol       Date:  2017-05-17       Impact factor: 5.650

7.  Significance of Vascular Endothelial Growth Factor Expression in the Bladder Urothelial Carcinoma and Its Association with Tumor Grade and Invasiveness.

Authors:  Anika Sadaf; Md Zillur Rahman; Pradip Bhattacharjee; M Shahab Uddin Ahamad; Sayeeda Nasreen
Journal:  Iran J Pathol       Date:  2021-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.